Help us: Donate
Follow us on:
×

Tag: CRISPR

March 31, 2020
Researchers have overcome a major limitation of the CRISPR-Cas9 gene editing system, which should allow previously inaccessible parts of the genome to be edited with ease. What is CRISPR-Cas9? Clustered regularly interspaced short palindromic repeats (CRISPR) is used in CRISPR-Cas9 and CRISPR-associated protein, a gene editing system that has created considerable excitement in the last...
February 28, 2020
The successful delivery of CRISPR/Cas9 modified immune cells to cancer patients represents the first U.S. clinical trial to test the gene editing approach in humans. Researchers from the Abramson Cancer Center of the University of Pennsylvania have published data suggesting that immune cells modified using the gene editing tool CRISPR/Cas9 are able to survive and...
November 29, 2019
For the November episode of the Journal Club, Dr. Oliver Medvedik reviewed a new study from a team of researchers including Professor George Church. The study saw the deployment of a multiple target gene therapy focused on 3 known longevity genes delivered via an adeno-associated virus. The focus was on mitigating T2 diabetes, heart failure, and kidney failure...
November 13, 2019
Recently, the first attempt in the United States to use the gene editing tool CRISPR to combat cancer appears to have gone well, according to the initial results of a small human trial to determine safety for the approach. Gene editing is a way to permanently change DNA in order to potentially cure a disease...
July 23, 2019
Recently, we had the opportunity to interview Professor George Church, a well-known geneticist and rejuvenation expert whom we have previously interviewed. Prof. Church's company, Rejuvenate Bio, will be launching a clinical trial to test a rejuvenation therapy in dogs this fall. In your recent paper on enabling large-scale genome editing, you talked about manipulating endogenous...
April 30, 2019
For the April edition of the Journal Club, we discussed the recent paper from the Salk Institute. The findings, published in the journal Nature Medicine, showcase a novel CRISPR/Cas9 genome-editing therapy that can suppress the accelerated aging observed in mice with Hutchinson-Gilford progeria syndrome. This treatment provides an important insight into the molecular pathways involved in accelerated aging,...